The UK medicines regulator has approved Pfizer’s marstacimab for patients aged 12 years or older with severe haemophilia A or B, offering a new subcutaneous treatment option.

The research team found that a specific muscle protein, known as MEF2C, is significantly reduced in muscle cells with CP.

Hympavzi is now approved in the U.K. for the prevention of bleeds in adults and adolescents with hemophilia A or B, without ...

Australia: In a significant development for Hemophilia B treatment, a multi-year follow-up study has shown that a single ...

or factor IX (hemophilia B) which are proteins required for blood to clot and to stop bleeding. Some patients with hemophilia can develop factor VIII or factor IX inhibitors (antibodies in the ...

Treatment with fidanacogene elaparvovec, a recombinant adeno-associated virus (AAV) vector developed for the treatment of hemophilia B, led to sustained expression of the high-activity factor IX ...

As with all products, the MHRA will keep its safety under close review. The Medicines and Healthcare products Regulatory ...

Qfitlia (fitusiran) is the first therapy for both hemophilia A or B, with or without inhibitors, available in the United ...

By: Dr. Vijay Ramanan Haemophilia B constitutes a severe rare genetic bleeding condition which interferes strongly with blood ...

Hemophilia is a rare but serious inherited disease. The constant risk of unexpected bleeding makes it a silent and persistent ...